Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (557)	1/24/2000 10:19:00 AM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 52153

Richard, I don't know who this Richard guy is either. But a number of people have been trying to enlighten me in private mail. Comparing that to some of the public comments, I feel great sympathy for the three blind men who had to describe and elephant and try to figure out what it was... :-) Of course, there're still too few people participating in my study to satisfy the FDA and unless enrollment really picks up, I fear you may never be approved for anything :-) That said, I appreciate your comments. I like infectious disease - we all have out perversions - and this one crossed my radar screen. It looks good to me so far, but I need to go and improve my knowledge base a bit. I'm progressing though; I now have a lot of knowledge about cows and teats and coupled with prior experience, I might become an expert some day :-) Thanks for the comments. I'll investigate further before I jump in with both feet. Torben

To: scaram(o)uche who wrote (557)	1/24/2000 8:00:00 PM
From: Miljenko Zuanic	Respond to of 52153

<<You might also see if Miljenko has commented lately, as he was following them. >> No I didn't seriously checked on CRXA for some time, only marginally from news. I did have tip from on-line friend on them, but was so busy with other staff that I passed. Anyway, I am for now bit less optimistic about cancer vaccines therapy than was 12-16 months ago. I would like to see some good results from any vaccine. RIBI was interesting as pilot-scale/manufacturing capability as well some technology (maybe few scientists/staff?). I do not think that their adjuvant was important to CRXA. Miljenko